UPDATE: Immunic Inc. (IMUX) Announces Positive Top-Line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting MS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. DPZ
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to UPDATE: Immunic Inc. (IMUX) Announces Positive Top-Line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting MS

Immunic Inc. (IMUX) Prices 5M Share Common Offering at $18/Sh

August 5, 2020 5:55 AM EDT

Immunic, Inc. (NASDAQ: IMUX) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.00 per share. The proceeds of the offering to the Company are expected to be $90.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the... More